Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

BOULDER, Colo., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ: NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at Baird’s Global Healthcare Conference and the Rodman & Renshaw 18th Annual Global Investment Conference.

Details of the two presentations are as follows:

Baird’s Global Healthcare Conference Date: Thursday, September 8th Location: The New York Palace, New YorkPresentation Time: 10:50 AM EDT

Rodman & Renshaw 18th Annual Global Investment ConferenceDate: Tuesday, September 13th  Location: The Lotte New York Palace Hotel, New YorkPresentation Time: 10:25 AM EDT

Individuals may access a live webcast of the conference presentations on the Nivalis website at www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event.

About Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

Contacts:

Investor Relations
John Graziano
1-646-378-2942
[email protected]

Media Relations
Lindsay Rocco
1-862-596-1304
[email protected]

Source: Nivalis Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ARGAN: Mr. Aymar de GERMAY is appointed at the Executive Board of ARGAN
• Sodexo - Financial report for First half Fiscal 2024 available
• Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program